Please type a plus sign (+) inside this box →	+
---	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/P	то		Complete if Known			
INFO	DMATIO		N 0011DE	Application Number			
INFORMATION DISCLOSURE				Filing Date			
STAT	STATEMENT BY APPLICANT			First Named Inventor	Reynold Homan		
				Group Art Unit	1614		
((	ise as many sh	neets as ne	cessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	A0000170-01-AJL		

Cite Io.1	Number (ii	nd Code <sup>2</sup>	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,
		known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	5,491,172		Helen T.Lee et al	02/13/1996	
	5,656,634		Chang et al	08/12/1997	
	5.596.001		Hamanaka et al	01/21/1997	·
	5.565.472		Hamanaka et al	10/15/1996	
	4.994.465		Trivedi	02/19/1991	
	4.716.175		Hoefle et al	12/29/1987	
	4.751.026		Hoefle et al	06/14/1988	
	4.722.927		Holmes	02/02/1988	
	5.116.848		Trivedi	05/26/1992	
	4.868.210		Trivedi	09/19/1989	
	4.948.806		Trivedi	08/14/1990	
	4.999.373		Trivedi	03/12/1991	
	5.030.653		Trivedi	07/09/1991	
	5.155.127		Trivedi	10/13/1992	
	4.923.896		Trivedi	05/08/1990	
	5.126.483		Sekiva et al l	06/30/1992	
	5,223,513		Meguro et al	06/29/1993	
	5.202.351		Sekiva et al	04/13/1993	
	5.015.644		Roth et al	05/14/1991	
		4.994,465 4.716.175 4.751.026 4.722.927 5.116.848 4.868.210 4.948.806 4.999.373 5.030.653 5.155.127 4.923.896 5.126.483 5.223.513 5.202.351	4.994,465 4.716.175 4.751.026 4.722.927 5.116.848 4.868.210 4.948.806 4.999.373 5.030.653 5.155.127 4.923.896 5.126.483 5.223.513 5.202.351	4.994,465       Trivedi         4.716.175       Hoefle et al         4.751.026       Hoefle et al         4.722.927       Holmes         5.116.848       Trivedi         4.868.210       Trivedi         4.948.806       Trivedi         4.999.373       Trivedi         5.030.653       Trivedi         5.155.127       Trivedi         4.923.896       Trivedi         5.126.483       Sekiva et all         5.202.3513       Meguro et al         5.202.351       Sekiva et al	4.994.465       Trivedi       02/19/1991         4.716.175       Hoefle et al       12/29/1987         4.751.026       Hoefle et al       06/14/1988         4.722.927       Holmes       02/02/1988         5.116.848       Trivedi       05/26/1992         4.868.210       Trivedi       09/19/1989         4.948.806       Trivedi       08/14/1990         4.999.373       Trivedi       03/12/1991         5.030.653       Trivedi       07/09/1991         5.155.127       Trivedi       10/13/1992         4.923.896       Trivedi       05/08/1990         5.126.483       Sekiva et all       06/30/1992         5.223.513       Meguro et al       06/29/1993         5.202.351       Sekiva et al       04/13/1993

116	Foreign Patent Docu			Date of Publication of	Pages, Columns, Lines,	
lo.òffic e³	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
EP	0399422	Al	Takeda Chemical Ind.	11/28/1990		$\top$
EP	0252524	A2	Warner-Lambert Co.	01/13/1988		
EP	0293880	B1	Warner-Lambert Co.	08/26/1992		†
EP	0297610	B1	Warner-Lambert Co.	03/13/1991	1	1
wo	9324458	Al	Pfizer Inc.	12/09/1993		1
wo	9104027	Al	Pfizer Inc.	04/04/1991		1
wo	9315058	A1	Pfizer Inc.	08/05/1993		1
EP	0699439	A2	Pfizer Inc.	03/06/1996		
	EP EP EP WO WO	EP 0252524 EP 0293880 EP 0297610 WO 9324458 WO 9104027 WO 9315058	EP 0252524 A2 EP 0293880 B1 EP 0297610 B1 WO 9324458 A1 WO 9104027 A1 WO 9315058 A1	EP         0252524         A2         Warner-Lambert Co.           EP         0293880         B1         Warner-Lambert Co.           EP         0297610         B1         Warner-Lambert Co.           WO         9324458         A1         Pfizer Inc.           WO         9104027         A1         Pfizer Inc.           WO         9315058         A1         Pfizer Inc.	EP         0399422         A1         Takeda Chemical Ind.         11/28/1990           EP         0252524         A2         Warner-Lambert Co.         01/13/1988           EP         0293880         B1         Warner-Lambert Co.         08/26/1992           EP         0297610         B1         Warner-Lambert Co.         03/13/1991           WO         9324458         A1         Pfizer Inc.         12/09/1993           WO         9104027         A1         Pfizer Inc.         04/04/1991           WO         9315058         A1         Pfizer Inc.         08/05/1993	EP         0399422         A1         Takeda Chemical Ind.         11/28/1990           EP         0252524         A2         Warner-Lambert Co.         01/13/1988           EP         0293880         B1         Warner-Lambert Co.         08/26/1992           EP         0297610         B1         Warner-Lambert Co.         03/13/1991           WO         9324458         A1         Pfizer Inc.         12/09/1993           WO         9104027         A1         Pfizer Inc.         04/04/1991           WO         9315058         A1         Pfizer Inc.         08/05/1993

			<u> </u>
Examiner	·	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

									$\overline{}$
Please	type	а	plus	sian	(+)	inside	this	box	 
	• •			- 0	٠,				т —

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Trademark Office: U.S. DEDAGTAFAT OF COMMISSION

.Und	er the Paperwork Reduction Act of 1995,	no persons are required to res	ond to a collection of informatio	ark Office: U.S. DEPARTMENT in unless it contains a valid OM	OF COMMERCE B control number.
$P_{\rm eff}^{\rm tree}$	Substitute for form 1449B/PTO		Co	mplete if Known	
			Application Number		

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet of 2

Complete if Known					
Application Number					
Filing Date					
First Named Inventor	Reynold Homan				
Group Art Unit	1614				
Examiner Name					
Attomey Docket Number	A0000170-01-AJL				

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2					
, Mir , Mir		REINDEL, JAMES F. ET AL., Toxicologic Effects of a Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor in Cynomolgus Monkeys, Toxicologic Pathology ISSN:0192-6233 Vol 22, Number 5, 1994 PP 510-518.						
·								
· ·								
Examiner Signature		Date Considered						

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.